Adaptimmune Therapeutics plc is a clinical-stage biopharmaceutical company dedicated to developing innovative cell therapies. Its primary focus is on addressing solid tumors in patients across the United States and the United Kingdom. At the core of its approach is the specific peptide enhanced affinity receptor (SPEAR) T-cell platform, designed to precisely identify cancer targets. The company's pipeline features several key candidates: ADP-A2M4 is in advanced clinical development, with Phase II trials underway for synovial sarcoma and myxoid round cell liposarcoma (SPEARHEAD-1), as well as for head and neck cancer (SPEARHEAD-2). Additionally, it is undergoing Phase I assessment for a wide range of cancers, including urothelial, melanoma, head and neck, ovarian, non-small cell lung, esophageal, gastric, synovial sarcoma, and MRCLS. ADP-A2AFP is currently in Phase I clinical trials for hepatocellular carcinoma. ADP-A2M4CD8, which utilizes SPEAR T-cells, is also in Phase I trials for treating lung, gastroesophageal, head and neck, ovarian, and bladder cancers. Adaptimmune has established a diverse portfolio of strategic collaborations, including a licensing and partnership agreement with GSK, and third-party collaborations with Noile-Immune Biotech Inc., Alpine Immune Sciences, Inc., and the National Center for Cancer Immune Therapy in Denmark. Further alliances include a strategic agreement with the MD Anderson Cancer Center and a co-development and co-commercialization agreement with Universal Cells, Inc. A significant strategic collaboration and license agreement with Genentech, Inc. and F. Hoffman-La Roche Ltd focuses on advancing personalized allogeneic T-cell therapies using aß T-cell receptors. Founded in 2008, Adaptimmune Therapeutics plc is headquartered in Abingdon, United Kingdom.